The differential response to anti IL-6 treatment in COVID-19 : the genetic counterpart
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Clinical and experimental rheumatology - 38(2020), 3 vom: 26. Mai, Seite 580 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Perricone, Carlo [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 04.06.2020 Date Revised 18.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM310344905 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310344905 | ||
| 003 | DE-627 | ||
| 005 | 20231225135907.0 | ||
| 007 | tu | ||
| 008 | 231225s2020 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1034.xml |
| 035 | |a (DE-627)NLM310344905 | ||
| 035 | |a (NLM)32452345 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Perricone, Carlo |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The differential response to anti IL-6 treatment in COVID-19 |b the genetic counterpart |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 04.06.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Adaptor Proteins, Signal Transducing |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 650 | 7 | |a Antigens, Differentiation, T-Lymphocyte |2 NLM | |
| 650 | 7 | |a CD69 antigen |2 NLM | |
| 650 | 7 | |a IL6 protein, human |2 NLM | |
| 650 | 7 | |a IL6R protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Lectins, C-Type |2 NLM | |
| 650 | 7 | |a Receptors, Interleukin-6 |2 NLM | |
| 650 | 7 | |a TRAF3IP2 protein, human |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Conigliaro, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Ciccacci, Cinzia |e verfasserin |4 aut | |
| 700 | 1 | |a Marcucci, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Cafaro, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Bartoloni, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Perricone, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Novelli, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Borgiani, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Gerli, Roberto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental rheumatology |d 1989 |g 38(2020), 3 vom: 26. Mai, Seite 580 |w (DE-627)NLM012613010 |x 0392-856X |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2020 |g number:3 |g day:26 |g month:05 |g pages:580 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2020 |e 3 |b 26 |c 05 |h 580 | ||